OpenNashEarnings

Health Care · NYSE: CAH

Cardinal Health earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends June · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q1 FY2027

Cardinal Health raised its fiscal 2027 outlook as brand and specialty pharma demand grew, a CVS Health distribution renewal was signed and a diabetes supplies acquisition was lined up.

Cardinal's pharmaceutical distribution business grew on brand and specialty drug sales from existing customers, helped by a better generics program. Its home-health, nuclear and logistics businesses (reported together as Other) grew across all three units. Medical products were flat: Cardinal Health Brand grew, but distribution and currency effects weighed. The company closed the Strive Medical acquisition, a multi-specialty supply provider focused on urology.

Read the Q1 FY2027 summary →Q1 FY2027 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$67.5B+5.5% y/yQ1 FY27
Q4 FY24: $59.9B (worked out from the annual figure)Q4 24$59.9BQ1 FY25: $52.3BQ1 25$52.3BQ2 FY25: $55.3BQ2 25$55.3BQ3 FY25: $54.9BQ3 25$54.9BQ4 FY25: $60.2B (worked out from the annual figure)Q4 25$60.2BQ1 FY26: $64.0BQ1 26$64.0BQ2 FY26: $65.6BQ2 26$65.6BQ1 FY27: $67.5BQ1 27$67.5B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$59.9B *
Q1 FY25$52.3B
Q2 FY25$55.3B
Q3 FY25$54.9B
Q4 FY25$60.2B *
Q1 FY26$64.0B
Q2 FY26$65.6B
Q1 FY27$67.5B
Diluted EPS (GAAP)$2.38+26.6% y/yQ1 FY27
Q1 FY25: $1.70Q1 25$1.70Q1 FY26: $1.88Q1 26$1.88Q1 FY27: $2.38Q1 27$2.38
Data
Q1 FY25$1.70
Q1 FY26$1.88
Q1 FY27$2.38

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.1%+0.1 pts y/yQ1 FY27
Q4 FY24: 0.7%Q4 240.7%Q1 FY25: 1.1%Q1 251.1%Q2 FY25: 1.0%Q2 251.0%Q3 FY25: 1.3%Q3 251.3%Q4 FY25: 0.7%Q4 250.7%Q1 FY26: 1.0%Q1 261.0%Q2 FY26: 1.1%Q2 261.1%Q1 FY27: 1.1%Q1 271.1%
Data
Q4 FY240.7%
Q1 FY251.1%
Q2 FY251.0%
Q3 FY251.3%
Q4 FY250.7%
Q1 FY261.0%
Q2 FY261.1%
Q1 FY271.1%
Free cash flow$1.2B+43.5% y/yQ1 FY27
Q4 FY24: $1.9BQ4 24$1.9BQ1 FY25: -$1.7BQ1 25-$1.7BQ2 FY25: -$495.0MQ2 25-$495.0MQ3 FY25: $2.8BQ3 25$2.8BQ4 FY25: $1.3BQ4 25$1.3BQ1 FY26: $865.0MQ1 26$865.0MQ2 FY26: $555.0MQ2 26$555.0MQ1 FY27: $1.2BQ1 27$1.2B
Data
Q4 FY24$1.9B
Q1 FY25-$1.7B
Q2 FY25-$495.0M
Q3 FY25$2.8B
Q4 FY25$1.3B
Q1 FY26$865.0M
Q2 FY26$555.0M
Q1 FY27$1.2B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q1 FY27
Revenue$59.9Bd$52.3B$55.3B$54.9B$60.2Bd$64.0B$65.6B$67.5B
Gross margin3.1%3.6%3.5%3.9%3.7%3.6%3.7%3.8%
Operating income$401.0Md$568.0M$549.0M$730.0M$428.0Md$668.0M$707.0M$753.0M
Operating margin0.7%1.1%1.0%1.3%0.7%1.0%1.1%1.1%
Net income$235.0Md$416.0M$400.0M$506.0M$239.0Md$450.0M$467.0M$554.0M
Diluted EPS—$1.70———$1.88—$2.38
Operating cash flow$2.1Bd-$1.6B-$396.0Md$2.9Bd$1.5Bd$973.0M$686.0Md$1.4B
Capital expenditure$193.0Md$90.0M$99.0Md$126.0Md$232.0Md$108.0M$131.0Md$157.0M
Free cash flow$1.9B-$1.7B-$495.0M$2.8B$1.3B$865.0M$555.0M$1.2B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings